Mergers & acquisitions
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.
Shares of General Electric jumped as much as 13 percent in trading this morning after Danaher Corporation announced it was acquiring the conglomerate’s biopharma business, GE Biopharma, for $21.4 billion.
This morning, Ipsen said it entered into an agreement with Clementia will help the company continue its transformation that is part of a key strategic objective to accelerate its rare disease pipeline.
Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, said his company is the only biotech company that has successfully commercialized a gene therapy for a genetic disease in the United States.
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.
Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health, Inc., a company that developed robotic endoscopic technologies that can be used in the treatment of lung cancer.
Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.
PRESS RELEASES